TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26181467

Group type: EXPERIMENTAL
Intervention: Blue-enriched indoor light (280 lux)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Blue-suppressed indoor light (240 lux)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Blue-enriched light exposure
Number of subjects: 29

Group type: COMPARATOR
Intervention: Baseline PSQI for females
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Subjective grading of indoor light quality
Number of subjects: 29
Study: 23494579

Group type: EXPERIMENTAL
Intervention: Whole egg consumption (3 eggs per day)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Yolk-free egg substitute
Number of subjects: 37
Study: 21995983

Group type: EXPERIMENTAL
Intervention: Selective laser trabeculoplasty (SLT)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Argon laser trabeculoplasty (ALT)
Number of subjects: 152
Study: 18319422

Group type: EXPERIMENTAL
Intervention: Empirical binomial hierarchical Bayesian model
Number of subjects: 0
Study: 17192686

Group type: EXPERIMENTAL
Intervention: VBP with mitomycin C
Number of subjects: 30

Group type: COMPARATOR
Intervention: VBP
Number of subjects: 30
Study: 14571187

Group type: EXPERIMENTAL
Intervention: Inactivated Mycobacterium vaccae (MV) vaccine
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control vaccine (CV)
Number of subjects: 39
Study: 10730042

Group type: EXPERIMENTAL
Intervention: Cleaning newborn infants with coconut oil
Number of subjects: 227

Group type: COMPARATOR
Intervention: Not being placed under radiant warmer before cleaning
Number of subjects: 227

Group type: COMPARATOR
Intervention: Lower labour room temperature
Number of subjects: 227

Group type: COMPARATOR
Intervention: Lower pre-cleaning body temperature
Number of subjects: 227

Group type: COMPARATOR
Intervention: Longer duration of cleaning
Number of subjects: 227
Study: 21594407

Group type: EXPERIMENTAL
Intervention: Peoscopy and treatment of male partners, condom use for one year (Group A, n=64)
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: No peoscopy, no treatment of male partners, condom use for one year (Group B, n=79)
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Peoscopy and treatment of male partners, no condom use (Group C, n=40)
Number of subjects: 246

Group type: COMPARATOR
Intervention: No peoscopy, no treatment of male partners, no condom use (Group D, n=63)
Number of subjects: 246
Study: 1598311

Group type: EXPERIMENTAL
Intervention: Recombinant human colony-stimulating factors (CSFs) including Granulocyte CSF and Granulocyte-macrophage CSF
Number of subjects: 0
Study: 6379319

Group type: EXPERIMENTAL
Intervention: Methenamine mandelate
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 30253723

Group type: EXPERIMENTAL
Intervention: Affirmative consent policy emphasizing the threat of punishment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Affirmative consent policy emphasizing a normative/moral message
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ergonomic workstation policy
Number of subjects: 0
Study: 27529226

Group type: EXPERIMENTAL
Intervention: Isoflavonoid‐rich herbal preparation (500 mg)
Number of subjects: 157
Study: 24619793

Group type: EXPERIMENTAL
Intervention: 1.5 g/m2 glutathione
Number of subjects: 185

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 185
Study: 20626402

Group type: EXPERIMENTAL
Intervention: Ezetimibe/simvastatin 10/20 mg (EZE/SIMVA)
Number of subjects: 618

Group type: COMPARATOR
Intervention: Rosuvastatin 10 mg (ROSUVA)
Number of subjects: 618

Group type: EXPERIMENTAL
Intervention: Ezetimibe/simvastatin 10/20 mg (EZE/SIMVA) in patients with T2DM
Number of subjects: 618

Group type: EXPERIMENTAL
Intervention: Ezetimibe/simvastatin 10/20 mg (EZE/SIMVA) in patients without T2DM
Number of subjects: 618
Study: 20346243

Group type: EXPERIMENTAL
Intervention: 3D volumetric ultrasonography
Number of subjects: 2

Group type: COMPARATOR
Intervention: 2D real-time ultrasonography
Number of subjects: 2
Study: 18441447

Group type: EXPERIMENTAL
Intervention: Rhythm control (n=155)
Number of subjects: 221

Group type: COMPARATOR
Intervention: Rate control (n=66)
Number of subjects: 221
Study: 16192765

Group type: EXPERIMENTAL
Intervention: AQUAVAN Injection (AQ) at doses of 5, 10, 15, 20, 25, or 30 mg/kg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: AQUAVAN Injection (AQ)
Number of subjects: 36

Group type: COMPARATOR
Intervention: PropofolD (50 mg/min)
Number of subjects: 36

Group type: COMPARATOR
Intervention: PropofolD
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: AQUAVAN Injection (AQ) and PropofolD
Number of subjects: 36
Study: 12548534

Group type: EXPERIMENTAL
Intervention: FK506
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (normal IL-2 production)
Number of subjects: 19
Study: 12103264

Group type: EXPERIMENTAL
Intervention: Biventricular pacing (BiV) in patients with sinus rhythm (SR)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Biventricular pacing (BiV) in patients with atrial fibrillation (AF)
Number of subjects: 131
Study: 10411363

Group type: EXPERIMENTAL
Intervention: Zofenopril (ACE inhibitor) given within 24 hours of symptom onset
Number of subjects: 1441
Study: 7586247

Group type: EXPERIMENTAL
Intervention: Enoxaparin (20 mg, 40 mg, 1 mg/kg, 2 mg/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nadroparin (7500 ICU, 10,000 ICU, 225 ICU/kg, 450 ICU/kg)
Number of subjects: 0
Study: 2138449

Group type: EXPERIMENTAL
Intervention: Fish oil supplementation
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (fractionated coconut oil)
Number of subjects: 16
Study: 7247630

Group type: EXPERIMENTAL
Intervention: Thioridazine
Number of subjects: 15

Group type: COMPARATOR
Intervention: Thiothixene
Number of subjects: 15
Study: 31299257

Group type: EXPERIMENTAL
Intervention: EndoRings
Number of subjects: 562

Group type: COMPARATOR
Intervention: Standard colonoscopy
Number of subjects: 562
Study: 31233395

Group type: EXPERIMENTAL
Intervention: Laparoscopic ileocaecal resection
Number of subjects: 143

Group type: COMPARATOR
Intervention: Infliximab
Number of subjects: 143
Study: 28728603

Group type: EXPERIMENTAL
Intervention: Social pressure covering letter (n=2223)
Number of subjects: 4447

Group type: COMPARATOR
Intervention: Control covering letter (n=2224)
Number of subjects: 4447
Study: 25586754

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Combination therapy (CBT + Sertraline)
Number of subjects: 45
Study: 23425352

Group type: EXPERIMENTAL
Intervention: Cognition-focused intervention (CA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: General education (control)
Number of subjects: 0
Study: 21073983

Group type: EXPERIMENTAL
Intervention: 60 mg oral codeine
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 19197541

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Paroxetine and Fluvoxamine
Number of subjects: 72
Study: 17539886

Group type: EXPERIMENTAL
Intervention: Young maternal age (<=18 years)
Number of subjects: 1393

Group type: EXPERIMENTAL
Intervention: Each year of increasing maternal age
Number of subjects: 1393

Group type: EXPERIMENTAL
Intervention: Young maternal age
Number of subjects: 1393
Study: 15448290

Group type: EXPERIMENTAL
Intervention: Advance notice letter
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Male sex
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Younger age
Number of subjects: 600

Group type: COMPARATOR
Intervention: No letter (control)
Number of subjects: 600
Study: 11166973

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral group intervention
Number of subjects: 253

Group type: COMPARATOR
Intervention: Treatment as usual comparison group
Number of subjects: 253
Study: 10188440

Group type: EXPERIMENTAL
Intervention: Philadelphia cervical collar
Number of subjects: 20

Group type: COMPARATOR
Intervention: Aspen cervical collar
Number of subjects: 20
Study: 8091317

Group type: EXPERIMENTAL
Intervention: ZD2138 (350 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 2456121

Group type: EXPERIMENTAL
Intervention: Transurethral prostatectomy
Number of subjects: 38

Group type: COMPARATOR
Intervention: Conservative management
Number of subjects: 38
Study: 28661585

Group type: EXPERIMENTAL
Intervention: Insulin glargine 300 U/mL (Gla‐300)
Number of subjects: 549

Group type: COMPARATOR
Intervention: Insulin glargine 100 U/mL (Gla‐100)
Number of subjects: 549

Group type: EXPERIMENTAL
Intervention: Insulin glargine 300 U/mL (Gla‐300) morning injection
Number of subjects: 549

Group type: COMPARATOR
Intervention: Insulin glargine 100 U/mL (Gla‐100) evening injection
Number of subjects: 549
Study: 27389565

Group type: EXPERIMENTAL
Intervention: Transcatheter direct mitral annuloplasty using the Cardioband device
Number of subjects: 45
Study: 24038831

Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Cognitive‐behavioral therapy
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Antidepressant medication
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Life event exposure
Number of subjects: 68
Study: 22643943

Group type: EXPERIMENTAL
Intervention: Total laryngectomy
Number of subjects: 15
Study: 20557511

Group type: EXPERIMENTAL
Intervention: 2 weeks of preoperative albendazole (ABZ) and praziquantel (PZQ)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 4 weeks of preoperative albendazole (ABZ) and praziquantel (PZQ)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 8 weeks of preoperative albendazole (ABZ) and praziquantel (PZQ)
Number of subjects: 45

Group type: COMPARATOR
Intervention: 0 weeks (control group)
Number of subjects: 45
Study: 17573782

Group type: EXPERIMENTAL
Intervention: Naltrexone treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 15728225

Group type: EXPERIMENTAL
Intervention: Novel six-drug combination chemotherapy for stage III disease
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: Standard treatment without alkylating agents for genitourinary nonbladder prostate tumors
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: Overall treatment strategy including selective avoidance of local therapy
Number of subjects: 503

Group type: COMPARATOR
Intervention: Previous treatment strategy (MMT 84)
Number of subjects: 503
Study: 15362475

Group type: EXPERIMENTAL
Intervention: Driver re-training sessions
Number of subjects: 65

Group type: COMPARATOR
Intervention: Waiting (control) group
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Overall driving scores
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Age correlation with driving scores
Number of subjects: 65
Study: 10989464

Group type: EXPERIMENTAL
Intervention: Intravenous ondansetron 5 mg/m2 plus dexamethasone 2-4 mg p.o.
Number of subjects: 438

Group type: EXPERIMENTAL
Intervention: Oral ondansetron 8 mg syrup plus dexamethasone 2-4 mg p.o.
Number of subjects: 438
Study: 9185752

Group type: EXPERIMENTAL
Intervention: L-ornithine-L-aspartate (OA) 20 g/d, infused intravenously for 4 hours over 7 consecutive days
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: L-ornithine-L-aspartate (OA) 20 g/d
Number of subjects: 126

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study: 1588146

Group type: EXPERIMENTAL
Intervention: Bacterial polysaccharide immune globulin (BPIG) at a dose of 0.5 ml/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bacterial polysaccharide immune globulin (BPIG) given at 2, 6, and 10 months of age
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Concurrent administration of diphtheria‐tetanus‐pertussis or Hib oligosaccharide‐diphtheria CRM197 conjugate vaccines
Number of subjects: 0
Study: 3896099

Group type: COMPARATOR
Intervention: Ceruletide (cholecystokinin‐like peptide) administered intramuscularly twice a day for 4 consecutive days to schizophrenic patients.
Number of subjects: 15

Group type: COMPARATOR
Intervention: Ceruletide (0.3 micrograms/kg or 0.6 micrograms/kg) administered intramuscularly to normal volunteers.
Number of subjects: 15

Group type: COMPARATOR
Intervention: Saline placebo administered intramuscularly to normal volunteers.
Number of subjects: 15
Study: 3269259

Group type: COMPARATOR
Intervention: Carbon monoxide exposure at 0 ppm
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Carbon monoxide exposure at 50 ppm
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Carbon monoxide exposure at 100 ppm
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Carbon monoxide exposure at 150 ppm
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Carbon monoxide exposure (all levels)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Carboxyhemoglobin concentrations
Number of subjects: 23
Study: 31795820

Group type: EXPERIMENTAL
Intervention: Video with animated pictographs
Number of subjects: 187

Group type: COMPARATOR
Intervention: Video with static pictographs
Number of subjects: 187

Group type: COMPARATOR
Intervention: Audiobooklet with static pictographs
Number of subjects: 187
Study: 31219772

Group type: EXPERIMENTAL
Intervention: Caffeine (6 mg/kg)
Number of subjects: 20
Study: 27539717

Group type: EXPERIMENTAL
Intervention: 5% acyclovir cream (test product T)
Number of subjects: 40

Group type: COMPARATOR
Intervention: 5% acyclovir cream (reference product R)
Number of subjects: 40
Study: 25050610

Group type: EXPERIMENTAL
Intervention: Vitamin D3 (2,000IU.d‐1)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 23380890

Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 26
Study: 20889359

Group type: EXPERIMENTAL
Intervention: Active local treatment (injection/hydroelectrophoresis)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Placebo local treatment
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Active local treatment (days 8 and 11) requested by placebo group
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Active therapy at 3-week follow-up
Number of subjects: 124
Study: 19745651

Group type: EXPERIMENTAL
Intervention: Overnight conversion to DVP ER
Number of subjects: 16

Group type: COMPARATOR
Intervention: Gradual conversion to DVP ER
Number of subjects: 16
Study: 16233932

Group type: EXPERIMENTAL
Intervention: Nicotinamide (1200 mg m(‐2) day(‐1))
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 12065742

Group type: EXPERIMENTAL
Intervention: Ro 32-7315 (2.5 mg/kg, i.p., twice daily)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Ro 32-7315 (5 mg/kg, i.p., twice daily)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Ro 32-7315 (10 mg/kg, i.p., twice daily)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Ro 32-7315 (20 mg/kg, i.p., twice daily)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Ro 32-7315 (450 mg, oral, single dose)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Ro 32-7315 (dose-dependent)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Ro 32-7315 (IC50)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Ro 32-7315 (cellular assay)
Number of subjects: 11
Study: 10404085

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide/methotrexate/fluorouracil (CMF)
Number of subjects: 274
Study: 7751529

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide nasal spray 0.06%, 84 micrograms per nostril three times a day for the first 6 months, with possible dose reduction in the last 6 months.
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide nasal spray 0.06%
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide nasal spray
Number of subjects: 96
Study: 2301192

Group type: EXPERIMENTAL
Intervention: Drug bulletin on renal colic treatment
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Drug bulletin on irritable bowel syndrome (IBS) treatment
Number of subjects: 186
Study: 6772011

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (50 mg of elemental zinc as zinc acetate per day)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 31837906

Group type: EXPERIMENTAL
Intervention: Intramuscular ondansetron 0.1 mg/kg plus ketamine 4 mg/kg
Number of subjects: 121

Group type: COMPARATOR
Intervention: Ketamine 4 mg/kg (control group)
Number of subjects: 121
Study: 28887269

Group type: EXPERIMENTAL
Intervention: Compassion-enhanced behaviors during death pronouncement
Number of subjects: 92

Group type: COMPARATOR
Intervention: Standard death pronouncement without compassion-enhanced behaviors
Number of subjects: 92
Study: 27388820

Group type: EXPERIMENTAL
Intervention: Tryton Side Branch Stent
Number of subjects: 133

Group type: COMPARATOR
Intervention: Standard provisional SB stenting (from TRYTON Pivotal RCT)
Number of subjects: 133
Study: 26641838

Group type: EXPERIMENTAL
Intervention: BMI more than 30 kg/m
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Changes in MVC over 3 months
Number of subjects: 139
Study: 23623914

Group type: EXPERIMENTAL
Intervention: Low-dose sodium nitrite (NaNO₂) (1.5 μmol/min for 20 min)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Low-dose sodium nitrite (NaNO₂) before ischemia
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Low-dose sodium nitrite (NaNO₂) during reperfusion
Number of subjects: 29
Study: 20652481

Group type: EXPERIMENTAL
Intervention: Infant formula with reduced protein content
Number of subjects: 1678

Group type: COMPARATOR
Intervention: Infant formula with higher protein content
Number of subjects: 1678
Study: 18990175

Group type: EXPERIMENTAL
Intervention: Solifenacin 5/10 mg
Number of subjects: 863

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 863
Study: 17158411

Group type: EXPERIMENTAL
Intervention: Diet and exercise therapy (treatment group)
Number of subjects: 27

Group type: COMPARATOR
Intervention: No therapy (control group)
Number of subjects: 27
Study: 14574034

Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dofetilide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Azimilide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral dofetilide, oral bolus-flecainide, propafenone, intravenous ibutilide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rate control drugs
Number of subjects: 0
Study: 10717333

Group type: EXPERIMENTAL
Intervention: Topotecan at intravenous doses of 1.5 mg/m(2)/day over 30 min for 5 days every 3 weeks (Arm A)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Topotecan at intravenous doses of 1.3 mg/m(2) for 5 days every 3 weeks (Arm B)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Arm A (1.5 mg/m(2)/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Arm B (1.3 mg/m(2))
Number of subjects: 0
Study: 8872288

Group type: EXPERIMENTAL
Intervention: High intensity exercise (HI; 85% of peak VO2)
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Low intensity exercise (LO; 50% of peak VO2)
Number of subjects: 186
Study: 1677368

Group type: EXPERIMENTAL
Intervention: Dopexamine (high dose: 4 micrograms/kg/min)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Dopexamine (intermediate dose: 2 micrograms/kg/min)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Dopexamine (low dose: 1 microgram/kg/min)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 6137386

Group type: EXPERIMENTAL
Intervention: Lormetazepam 0.5 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Lormetazepam 1 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Lormetazepam 2 mg
Number of subjects: 12
Study: 31867608

Group type: EXPERIMENTAL
Intervention: Extracorporeal shockwave therapy (0.2 mJ/mm2) once a week for four weeks in addition to standard physical rehabilitation (n = 12)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Botulinum toxin‐A injection (0.5-2 U/kg/muscle group with maximum dose of 12 U/kg/body weight) once at entry besides standard physical rehabilitation (n = 13)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Standard physical rehabilitation (control group; n = 13)
Number of subjects: 38
Study: 31365529

Group type: EXPERIMENTAL
Intervention: 1.8 mL of 4% articaine with 1:100,000 epinephrine
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 3.6 mL of 4% articaine with 1:100,000 epinephrine
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 1.8 mL of PDL injection
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 3.6 mL of PDL injection
Number of subjects: 90
Study: 29673271

Group type: EXPERIMENTAL
Intervention: Beyond Silence (6 in-person, 2-hour sessions plus 5 online sessions)
Number of subjects: 192

Group type: COMPARATOR
Intervention: Mental Health First Aid (standardized 2-day training program)
Number of subjects: 192
Study: 27054365

Group type: EXPERIMENTAL
Intervention: Catheterization threshold of 500 ml
Number of subjects: 721

Group type: COMPARATOR
Intervention: Catheterization threshold of 800 ml
Number of subjects: 721
Study: 24597730

Group type: EXPERIMENTAL
Intervention: Additional lesions in the interpulmonary isthmus (group II, n = 38)
Number of subjects: 76

Group type: COMPARATOR
Intervention: No further ablation (group I, n = 38)
Number of subjects: 76
Study: 22155768

Group type: EXPERIMENTAL
Intervention: Quadrivalent HPV vaccine (qHPV vaccine; Gardasil)
Number of subjects: 4065
Study: 20388140

Group type: EXPERIMENTAL
Intervention: Whey protein supplementation
Number of subjects: 17

Group type: COMPARATOR
Intervention: Soy protein (control)
Number of subjects: 17
Study: 18489430

Group type: EXPERIMENTAL
Intervention: Computer-assisted dosage
Number of subjects: 13219

Group type: COMPARATOR
Intervention: Medical staff dosage
Number of subjects: 13219
Study: 16197758

Group type: EXPERIMENTAL
Intervention: Ultrasonic scaler
Number of subjects: 40

Group type: COMPARATOR
Intervention: Hand-activated scaling instruments
Number of subjects: 40
Study: 12803269

Group type: EXPERIMENTAL
Intervention: metoprolol 2 mg
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: lidocaine 20 mg
Number of subjects: 90

Group type: COMPARATOR
Intervention: saline 2 mL
Number of subjects: 90
Study: 10368895

Group type: EXPERIMENTAL
Intervention: Neovir (interferonogenic immunomodulator)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Routine complex treatment
Number of subjects: 32
Study: 8616033

Group type: COMPARATOR
Intervention: Conventional maintenance (arm A)
Number of subjects: 358

Group type: COMPARATOR
Intervention: More intensive regimen (arm B)
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 358